Patent · US Expired

Method and system for use in treating a patient with a biological substance to optimize therapy and prevent an adverse response

US6581607B2 · kind B2 · utility

16Cited by
1References
35Claims
0Family size

Assignee

Inventors

Key dates

Filing dateJul 27, 2001
Grant dateJun 24, 2003
Priority date
Expiry dateJul 27, 2021

Classification

  • Technology area (CPC A)Human Necessities
  • CPC primaryA61P35/00
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

A method, system and apparatus for use in treating a patient receiving a biological substance, such as a cancer vaccine, to optimize therapy and prevent an adverse response. This system employs surrogate markers or indicators including blood levels of the vaccine to determine the next required dose for a patient. Since the surrogate markers may be employed as a percent change in status, virtually any indicator can be used. Surrogate markers could include any measure of the effectiveness of the vaccine's action. Given the effectiveness of the vaccine's action relative to the surrogate markers, a change in vaccine dose is calculated by the system. Conversely, by employing this system, one could determine the expected result of the vaccine dose change on the surrogate markers.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.